News

April 12, 2019

Arbitration Commercial litigation Corporate / M&A Employment law EU & Competition Healthcare IP & technology Life sciences Patents and technology Private equity and venture capital Real estate Trade marks, designs and advertising

Legal 500 highlights 24 BarentsKrans-laywers in the 2019-edition

This week Legal 500 released their 2019 rankings. As in previous years, BarentsKrans is mentioned several times in this leading, international guide for the legal profession. Again we are beyond proud and grateful of these honourable mentions. Developing Legal 500 rankings Legal 500 highlights those lawyers that provide the most cutting edge and innovative advice

March 26, 2018

Patents and technology Pharma & regulatory

Pharma update: tadalafil patent invalidated

The District Court of The Hague has invalidated ICOS’ patent EP 1 173 181 B3 (‘EP ‘181’) claiming a dosage range of tadalafil for the treatment of sexual dysfunction. Icos Corporation (‘Icos’), an Eli Lilly and Company subsidiary, distributes the medicinal product Cialis® containing tadalafil for the treatment of sexual dysfunction in adult men. EP

November 9, 2017

Patents and technology Pharma & regulatory Supreme court litigation

Pharma update: Indirect infringement of Swiss type claims is possible

In its judgment of 3 November 2017 in the case between Merck Sharp & Dohme (‘MSD’) and Teva, the Dutch Supreme Court ruled (ECLI:NL:HR:2017:2807) that indirect infringement of a ‘Swiss type’ second medical use patent claim is possible. In addition, the Supreme Court found that there is no difference in the scope of protection of second

November 7, 2017

Patents and technology Pharma & regulatory

Generic Pemetrexed Diacid infringes patent Pemetrexed Disodium

In two judgments of 24 October 2017, the Provisions Judge of the District Court in The Hague held that Teva’s and Fresenius Kabi’s generic pemetrexed diacid products infringe EP 1 313 508 (‘EP ‘508’) of Eli Lilly. EP ‘508 relates to the use of pemetrexed disodium in combination with vitamin B12 for the treatment of certain

October 6, 2016

IP & technology Patents and technology

Pharma update: MSD and Teva plead on subgroup indication patents

In its decision of 14 July 2015, the Court of Appeal of The Hague had decided that there is a difference in the scope of protection of second medical use patents and subgroup indication patents. On 30 September 2016, Merck Sharp & Dohme (‘MSD’) and Teva pleaded their case before the Dutch Supreme Court. The

EN